Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence.
- DOI
- 10.1007/s10549-008-9970-z
- Published
- 2009 Mar
- Container
- Breast cancer research and treatment
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10549-008-9970-z,
title = {Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence.},
author = {Wildiers H and Dirix L and Neven P and Prové A and Clement P and Squifflet P and Amant F and Skacel T and Paridaens R},
year = {2009},
journal = {Breast cancer research and treatment},
doi = {10.1007/s10549-008-9970-z},
url = {https://doi.org/10.1007/s10549-008-9970-z}
}RIS
TY - JOUR TI - Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. AU - Wildiers H AU - Dirix L AU - Neven P AU - Prové A AU - Clement P AU - Squifflet P AU - Amant F AU - Skacel T AU - Paridaens R PY - 2009 JO - Breast cancer research and treatment DO - 10.1007/s10549-008-9970-z UR - https://doi.org/10.1007/s10549-008-9970-z ER -
APA
H, W., L, D., P, N., A, P., P, C., P, S., F, A., T, S., & R, P. (2009). Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-008-9970-z
Source records
- pubmed · retrieved 2026-09-26T07:55:24.014Z